Guardant Health (GH) Revenue & Revenue Breakdown
Guardant Health Revenue Highlights
Latest Revenue (Y)
$982.02M
Latest Revenue (Q)
$265.20M
Main Segment (Y)
Oncology
Main Geography (Y)
UNITED STATES
Guardant Health Revenue by Period
Guardant Health Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2025-12-31 | $982.02M | 32.88% |
| 2024-12-31 | $739.02M | 31.04% |
| 2023-12-31 | $563.95M | 25.45% |
| 2022-12-31 | $449.54M | 20.31% |
| 2021-12-31 | $373.65M | 30.32% |
| 2020-12-31 | $286.73M | 33.75% |
| 2019-12-31 | $214.38M | 136.52% |
| 2018-12-31 | $90.64M | 81.85% |
| 2017-12-31 | $49.84M | 97.40% |
| 2016-12-31 | $25.25M | - |
Guardant Health generated $982.02M in revenue during NA 2025, up 32.88% compared to the previous quarter, and up 342.49% compared to the same period a year ago.
Guardant Health Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-09-30 | $265.20M | 14.27% |
| 2025-06-30 | $232.09M | 14.06% |
| 2025-03-31 | $203.47M | 0.82% |
| 2024-12-31 | $201.81M | 5.40% |
| 2024-09-30 | $191.48M | 8.04% |
| 2024-06-30 | $177.24M | 5.19% |
| 2024-03-31 | $168.49M | 8.67% |
| 2023-12-31 | $155.05M | 8.41% |
| 2023-09-30 | $143.03M | 4.29% |
| 2023-06-30 | $137.15M | 6.55% |
| 2023-03-31 | $128.71M | 1.44% |
| 2022-12-31 | $126.89M | 8.08% |
| 2022-09-30 | $117.40M | 7.57% |
| 2022-06-30 | $109.14M | 13.57% |
| 2022-03-31 | $96.10M | -11.11% |
| 2021-12-31 | $108.11M | 14.06% |
| 2021-09-30 | $94.78M | 2.91% |
| 2021-06-30 | $92.10M | 17.08% |
| 2021-03-31 | $78.67M | 0.45% |
| 2020-12-31 | $78.32M | 5.02% |
| 2020-09-30 | $74.57M | 12.41% |
| 2020-06-30 | $66.33M | -1.74% |
| 2020-03-31 | $67.51M | 7.33% |
| 2019-12-31 | $62.90M | 3.37% |
| 2019-09-30 | $60.85M | 12.73% |
| 2019-06-30 | $53.98M | 47.25% |
| 2019-03-31 | $36.66M | 11.50% |
| 2018-12-31 | $32.87M | 51.54% |
| 2018-09-30 | $21.69M | 11.92% |
| 2018-06-30 | $19.38M | 16.12% |
| 2018-03-31 | $16.69M | -16.55% |
| 2017-12-31 | $20.00M | 79.68% |
| 2017-09-30 | $11.13M | 9.18% |
| 2017-06-30 | $10.20M | 9.00% |
| 2017-03-31 | $9.35M | - |
Guardant Health generated $265.20M in revenue during Q3 2025, up 14.27% compared to the previous quarter, and up 149.63% compared to the same period a year ago.
Guardant Health Revenue Breakdown
Guardant Health Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 25 | Dec 24 |
|---|---|---|
| Licensing & Other | $8.56M | - |
| Oncology | $683.60M | - |
| Biopharma & Data | $210.13M | - |
| Screening | $79.73M | - |
| Reportable Segment | - | $739.02M |
Guardant Health's latest annual revenue breakdown by segment (product or service), as of Dec 25: Oncology (69.61%), Biopharma & Data (21.40%), Screening (8.12%), and Licensing & Other (0.87%).
Quarterly Revenue by Product
| Product/Service | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Licensing & Other | $2.18M | $1.95M | $2.57M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Biopharma & Data | $54.01M | $54.73M | $56.02M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Screening | $35.13M | $24.11M | $14.81M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Oncology | $189.95M | $184.40M | $158.69M | $150.56M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| UNITED STATES | - | - | - | - | $129.26M | $118.91M | $117.81M | $111.10M | $100.84M | $90.87M | $101.97M | $90.42M | $87.87M | $72.30M | $73.01M | $65.61M | $61.42M | $64.61M | $59.40M | $54.67M |
| Non-US | - | - | - | - | $7.89M | $9.80M | $9.08M | $6.31M | $8.31M | $5.23M | $6.14M | $4.36M | $4.23M | $6.37M | $5.31M | $8.96M | $4.91M | $2.90M | $3.50M | $6.17M |
Guardant Health's latest quarterly revenue breakdown by segment (product or service), as of Dec 25: Oncology (67.53%), Biopharma & Data (19.20%), Screening (12.49%), and Licensing & Other (0.78%).
Guardant Health Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| UNITED STATES | $923.28M | $697.16M | $526.52M | $420.62M | $352.56M |
| Non-US | $58.74M | $41.85M | $37.42M | $28.92M | $21.09M |
Guardant Health's latest annual revenue breakdown by geography, as of Dec 25: UNITED STATES (94.02%), and Non-US (5.98%).
Quarterly Revenue by Country
| Country | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| UNITED STATES | $263.55M | $249.44M | $216.68M | $193.61M | $359.71M | $180.10M | $157.35M | $142.62M | $135.74M | $129.26M | $118.91M | $117.81M | $111.10M | $100.84M | $90.87M | $101.97M | $90.42M | $87.87M | $72.30M | $73.01M |
| Non-US | $17.72M | $15.76M | $15.40M | $9.86M | $19.34M | $11.37M | $11.14M | $12.44M | $7.29M | $7.89M | $9.80M | $9.08M | $6.31M | $8.31M | $5.23M | $6.14M | $4.36M | $4.23M | $6.37M | $5.31M |
Guardant Health's latest quarterly revenue breakdown by geography, as of Dec 25: UNITED STATES (93.70%), and Non-US (6.30%).
Guardant Health Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| VTRS | Viatris | $14.30B | $3.76B |
| SOLV | Solventum | $8.32B | $2.10B |
| ICLR | ICON Public | $8.12B | $2.09B |
| EHC | Encompass Health | $5.94B | $1.48B |
| EXAS | Exact Sciences | $3.25B | $850.74M |
| RVTY | Revvity | $2.86B | $698.95M |
| QGEN | Qiagen | $1.97B | $458.80M |
| GH | Guardant Health | $982.02M | $265.20M |
| IONS | Ionis Pharmaceuticals | $944.00M | $156.72M |
| BBIO | BridgeBio Pharma | $362.37M | $108.11M |
| ASND | Ascendis Pharma | $266.72M | $95.89M |